Rallybio (NASDAQ:RLYB) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Rallybio (NASDAQ:RLYB) announced its quarterly earnings data on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02, Zacks reports. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.15 million.

Rallybio Stock Performance

Shares of NASDAQ RLYB opened at $0.66 on Friday. The firm has a market capitalization of $27.22 million, a PE ratio of -0.41 and a beta of -1.45. Rallybio has a fifty-two week low of $0.62 and a fifty-two week high of $3.46. The stock’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $0.98.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Rallybio in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Rallybio presently has a consensus rating of “Moderate Buy” and an average target price of $9.75.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.